FEMASYS INC

Company Overview

Femasys Inc. is a woman‑founded biomedical device company focused on in‑office reproductive and women’s health solutions, marketing FemaSeed (directional intratubal insemination), FemVue (saline‑air tubal assessment), FemCerv and FemCath, and developing FemBloc, a non‑surgical permanent contraception system. The company combines in‑house R&D and manufacturing at its Suwanee, GA facility (QSR/QMS compliant) with a targeted commercial rollout via a small direct salesforce in North America and international distributors. Recent commercial traction produced revenue growth (2024 revenue $1.63M; Q2 2025 YTD growth ~52%), while management is investing heavily in the FemBloc pivotal trial and commercial expansion, producing widening losses and a tight cash runway into Q3–Q4 2025. Key operational drivers are clinical/regulatory milestones (FDA pivotal, CE mark, EU MDR approvals), reimbursement/CPT coding progress, and manufacturing/supplier concentration risks.

Executive Compensation Practices

As a small, clinical‑stage medical device company, Femasys’ pay programs are likely equity‑heavy with smaller cash salaries and larger long‑term incentives (stock options/RSUs) and milestone‑based awards tied to regulatory and commercial outcomes. Given management emphasis on driving FemBloc enrollment and commercialization, incentive metrics are likely to include trial enrollment and interim analysis milestones, FDA/CE approvals, product revenue growth (FemaSeed/FemVue), and reimbursement/CPT coding achievements rather than short‑term GAAP profitability. Cash constraints and frequent dilutive financings (ATMs, offerings, convertible notes) increase the probability that equity awards form the bulk of upside for executives and may be structured with vesting linked to specific regulatory/commercial events. Accounting and financing features called out in MD&A (ASC 606 timing, convertible note discount amortization, pricing restrictions) can materially affect reported metrics used for bonus calculations and the realized value of equity compensation.

Insider Trading Considerations

Insider transactions at Femasys should be monitored for timing around material clinical and regulatory events (FemBloc enrollment milestones, interim analysis at 300, FDA or reimbursement news), which are highly material for a small device maker and likely to move the stock. The company’s active use of ATMs, recent public/private placements and outstanding convertible notes/warrants creates multiple potential sources of dilution and selling pressure when conversions or warrant exercises occur; insiders may also sell to meet liquidity needs given a short runway. Watch for 10b5‑1 plans, blackout‑period disclosures and Section 16 filings—absence of planned selling programs or sales immediately before major announcements can be a signal; conversely, insider buys during liquidity crunches are a stronger bullish signal for conviction. Finally, material nonpublic trial data and regulatory interactions are legally sensitive, so trading windows and insider trading policies around those events are likely to be strictly enforced.